98 results
8-K
EX-99.1
ATHA
Athira Pharma, Inc.
17 May 24
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
5:00pm
materials have been posted to the Investor Relations section of Athira’s website (http://investors.athira.com/): the Zoom meeting information for the final
DEFA14A
ATHA
Athira Pharma, Inc.
9 Apr 24
Additional proxy soliciting materials
8:34am
Materials
Soliciting Material under §240.14a-12
ATHIRA PHARMA, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy … materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
PRE 14A
h6bf64m4ouiii
28 Mar 24
Preliminary proxy
8:47am
8-K
EX-10.1
o8ak ddaj88o0d
22 Feb 24
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
4:10pm
8-K
EX-10.1
3mtjm
8 Jan 24
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
7:11am
8-K
EX-10.3
u1wyisvppkrklz4biffc
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
DEFA14A
16cr773tf6k j46
5 Apr 23
Additional proxy soliciting materials
7:18am
DEFA14A
ltyw9ss d510u
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
brqk4
16 May 22
Additional proxy soliciting materials
6:32pm
DFAN14A
qcsyghzvib w6
16 May 22
Additional proxy materials by non-management
2:04pm